Company research
ANI PHARMACEUTICALS INC
CIK 1023024Updated Nov 9, 2026
SecurityANIP · NASDAQ · equity
Name history
BIOSANTE PHARMACEUTICALS INC · through Jul 18, 2013BEN ABRAHAM TECHNOLOGIES INC · through Dec 23, 1999
ANIP price & chart
Loading TradingView…
NASDAQ:ANIP on TradingView ↗About the company
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
In the news
ANI Pharmaceuticals to Present at September Investor Conferences ↗
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other Events
Items 1.01, 2.03, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,408,152,000Source | 1,287,377,000Source | 1,494,112,000Source | 1,343,001,000Source | 920,753,000Source | 1,421,970,000Source | 1,292,428,000Source | 914,524,000Source | 1,440,377,000Source | 1,283,697,000Source | 904,422,000Source | 760,087,000Source |
| Property, Plant and Equipment, NetUSD | 63,560,000Source | 56,704,000Source | 73,223,000Source | 59,247,000Source | 51,640,000Source | 67,115,000Source | 58,179,000Source | 48,526,000Source | 62,476,000Source | 56,863,000Source | 44,593,000Source | 43,246,000Source |
| GoodwillUSD | 62,480,000Source | 60,426,000Source | 62,480,000Source | 60,533,000Source | 28,221,000Source | 62,480,000Source | 60,662,000Source | 28,221,000Source | 62,480,000Source | 59,990,000Source | 28,221,000Source | 28,221,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 499,817,000Source | 569,825,000Source | 449,857,000Source | 520,320,000Source | 183,078,000Source | 467,161,000Source | 538,495,000Source | 196,044,000Source | 479,526,000Source | 541,834,000Source | 209,009,000Source | 251,635,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 262,610,000Source | 144,982,000Source | 360,212,000Source | 217,833,000Source | 240,110,000Source | 311,176,000Source | 149,802,000Source | 228,597,000Source | 285,585,000Source | 144,861,000Source | 221,121,000Source | 48,228,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 252,617,000Source | 196,361,000Source | 274,469,000Source | 225,654,000Source | 166,091,000Source | 255,432,000Source | 220,334,000Source | 172,418,000Source | 281,082,000Source | 221,726,000Source | 162,079,000Source | 165,438,000Source |
| Inventory, NetUSD | 146,475,000Source | 148,042,000Source | 143,149,000Source | 138,315,000Source | 125,448,000Source | 143,468,000Source | 137,408,000Source | 113,837,000Source | 143,067,000Source | 136,782,000Source | 111,196,000Source | 105,355,000Source |
| Assets, CurrentUSD | 698,402,000Source | 521,297,000Source | 825,433,000Source | 602,630,000Source | 555,460,000Source | 747,084,000Source | 536,290,000Source | 540,557,000Source | 753,117,000Source | 527,684,000Source | 519,816,000Source | 344,261,000Source |
| Other Assets, NoncurrentUSD | 12,497,000Source | 11,464,000Source | 11,624,000Source | 8,246,000Source | 12,848,000Source | 11,575,000Source | 10,313,000Source | 13,569,000Source | 13,706,000Source | 12,220,000Source | 12,072,000Source | 11,361,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 902,335,000Source | 856,579,000Source | 896,900,000Source | 881,394,000Source | 440,143,000Source | 859,670,000Source | 848,958,000Source | 437,711,000Source | 899,653,000Source | 855,167,000Source | 446,823,000Source | 421,547,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 586,230,000Source | 510,899,000Source | 620,249,000Source | 541,899,000Source | 532,497,000Source | 608,429,000Source | 531,055,000Source | 523,628,000Source | 596,036,000Source | 519,653,000Source | 514,103,000Source | 403,901,000Source |
| Retained Earnings (Accumulated Deficit)USD | -50,589,000Source | -89,597,000Source | 31,104,000Source | -76,862,000Source | -65,025,000Source | 6,393,000Source | -85,004,000Source | -62,331,000Source | -23,099,000Source | -100,279,000Source | -80,132,000Source | -97,286,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,811,000Source | 5,366,000Source | -327,000Source | 3,312,000Source | 8,328,000Source | 479,000Source | 3,610,000Source | 9,406,000Source | 1,033,000Source | 5,344,000Source | 8,857,000Source | 12,168,000Source |
| Stockholders' Equity Attributable to ParentUSD | 505,817,000Source | 405,948,000Source | 597,212,000Source | 436,757,000Source | 455,760,000Source | 562,300,000Source | 418,620,000Source | 451,963,000Source | 540,724,000Source | 403,680,000Source | 432,749,000Source | 313,690,000Source |
| Liabilities and EquityUSD | 1,408,152,000Source | 1,287,377,000Source | 1,494,112,000Source | 1,343,001,000Source | 920,753,000Source | 1,421,970,000Source | 1,292,428,000Source | 914,524,000Source | 1,440,377,000Source | 1,283,697,000Source | 904,422,000Source | 760,087,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 270,555,000Source | 189,933,000Source | 283,655,000Source | 236,835,000Source | 139,978,000Source | 239,510,000Source | 201,815,000Source | 136,889,000Source | 278,112,000Source | 193,680,000Source | 145,477,000Source | 99,439,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 1,923,000Source | 1,799,000Source | 1,561,000Source | 684,000Source |
| Accounts Payable, CurrentUSD | 69,795,000Source | 60,890,000Source | 73,830,000Source | 54,569,000Source | 48,681,000Source | 69,694,000Source | 53,058,000Source | 49,430,000Source | 62,583,000Source | 45,656,000Source | 36,683,000Source | 29,305,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 9,173,000Source | 4,393,000Source | 4,111,000Source | 1,381,000Source |
| Other Liabilities, NoncurrentUSD | 11,270,000Source | 6,944,000Source | 15,535,000Source | 6,696,000Source | 4,679,000Source | 16,450,000Source | 7,020,000Source | 5,055,000Source | 12,164,000Source | 5,781,000Source | 4,809,000Source | 1,381,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 13,951,000Source | 17,814,000Source | 16,575,000Source | 14,761,000Source | 6,917,000Source | 13,735,000Source | 12,029,000Source | 7,430,000Source | 16,803,000Source | 13,735,000Source | 5,606,000Source | 5,394,000Source |
| Long-term Debt, Current MaturitiesUSD | 15,241,000Source | 7,152,000Source | 21,329,000Source | 13,216,000Source | 850,000Source | 19,298,000Source | 11,193,000Source | 850,000Source | 17,268,000Source | 9,172,000Source | 850,000Source | 850,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 297,677,000Source | 312,918,000Source | 280,155,000Source | 301,484,000Source | 284,394,000Source | 285,996,000Source | 305,294,000Source | 284,607,000Source | 291,840,000Source | 309,108,000Source | 284,819,000Source | 285,669,000Source |
| Operating Lease, Right-of-Use Asset | —Source | — | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 29,492,000Source | 15,681,000Source | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,191,000Source | 8,868,000Source | 37,929,000Source | 29,344,000Source | 20,652,000Source | 14,599,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -25,528,000Source | -1,782,000Source | 58,530,000Source | 21,087,000Source | -3,359,000Source | 36,912,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 437,000Source | 625,000Source | 5,961,000Source | 21,287,000Source | 5,841,000Source | 23,626,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 5,358,000Source | 5,549,000Source | 15,156,000Source | 479,000Source | 7,552,000Source | 5,038,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 11,787,000Source | -22,999,000Source | -11,576,000Source | -15,232,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 58,375,000Source | 34,991,000Source | 185,225,000Source | 64,017,000Source | 118,959,000Source | -31,203,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 33,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -11,324,000Source | -19,846,000Source | -34,321,000Source | -404,719,000Source | -18,511,000Source | -15,738,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 6,074,000Source | 2,474,000Source | 13,835,000Source | 16,236,000Source | 8,868,000Source | 8,876,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 19,755,000Source | 10,003,000Source | 12,209,000Source | 10,959,000Source | 4,987,000Source | 1,959,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -21,616,000Source | -9,906,000Source | -9,944,000Source | 264,945,000Source | 67,439,000Source | -5,126,000Source |
| Dividends paid | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 25,591,000Source | 4,942,000Source | 140,727,000Source | -76,227,000Source | 167,887,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 262,646,000Source | 145,017,000Source | 360,247,000Source | 217,833,000Source | 311,212,000Source | 149,836,000Source | 285,621,000Source | 144,894,000Source | 221,121,000Source | 53,234,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 7,824,000Source | 8,895,000Source | 26,929,000Source | 24,379,000Source | 31,431,000Source | 21,477,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -6,065,000Source | 285,000Source | 17,674,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 156,000Source | -297,000Source | -233,000Source | -470,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 14,300,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 2,364,000Source | 2,363,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 358,000Source | 324,000Source | 1,356,000Source | 642,000Source | 3,922,000Source | 3,961,000Source |
| Amortization of Intangible AssetsUSD | — | — | 20,400,000Source | 13,900,000Source | 17,400,000Source | 21,100,000Source | 18,700,000Source | 20,700,000Source | 82,500,000Source | 60,300,000Source | 52,300,000Source | 49,500,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 8,900,000Source | 7,400,000Source | 7,500,000Source | 7,400,000Source |
| Other Depreciation and AmortizationUSD | — | — | — | — | — | — | — | — | 91,417,000Source | 67,731,000Source | 59,791,000Source | 59,653,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 3,140,000Source | 1,355,000Source | 741,000Source | 332,000Source | 5,753,000Source | -921,000Source | 2,824,000Source | 6,307,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -295,000Source | 0Source | — | — | — | — | -382,000Source | — | — | — |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 750,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | 0Source | -382,000Source | 5,347,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source | — | 0Source | — | 0Source | — | 5,347,000Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | -7,468,000Source | — | — | — | — | 0Source | -7,468,000Source | 0Source | — |
| GoodwillUSD | — | — | 62,480,000Source | 60,426,000Source | 62,480,000Source | 60,533,000Source | 62,480,000Source | 60,662,000Source | 62,480,000Source | 59,990,000Source | 28,221,000Source | 28,221,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 0Source | — | — | — | — | 800,000Source | 3,600,000Source | 0Source | 112,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 800,000Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 4,000,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 7,183,000Source | -7,332,000Source | 12,386,000Source | 1,976,000Source | 10,729,000Source | 4,306,000Source | 17,454,000Source | -3,690,000Source | 1,093,000Source | -14,769,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 26,617,000Source | -24,166,000Source | 24,711,000Source | 8,549,000Source | 29,492,000Source | 15,681,000Source | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 26,273,000Source | -24,572,000Source | 23,000,000Source | 7,323,000Source | 29,492,000Source | 15,275,000Source | 77,180,000Source | -20,147,000Source | 17,154,000Source | -49,521,000Source |
| Other Interest and Dividend IncomeUSD | — | — | 1,257,000Source | 1,652,000Source | 1,007,000Source | 1,237,000Source | 1,005,000Source | 1,238,000Source | 4,874,000Source | 6,266,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -853,000Source | -2,535,000Source | -468,000Source | 1,739,000Source | -651,000Source | 198,000Source | 1,934,000Source | -4,033,000Source | -159,000Source | 670,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 80,555,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 2,202,000Source | 2,534,000Source | 13,604,000Source | 6,488,000Source | 8,996,000Source | 1,458,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 227,813,000Source | 148,332,000Source | 266,044,000Source | 211,371,000Source | 237,462,000Source | 197,122,000Source | 883,366,000Source | 614,376,000Source | 486,816,000Source | 316,385,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 76,656,000Source | 79,075,000Source | 91,661,000Source | 81,771,000Source | 73,655,000Source | 76,528,000Source | 317,745,000Source | 249,636,000Source | 161,697,000Source | 124,044,000Source |
| Operating Income (Loss)USD | — | — | 36,240,000Source | -20,519,000Source | 40,460,000Source | 13,892,000Source | 38,888,000Source | 26,194,000Source | 111,093,000Source | 584,000Source | 46,971,000Source | -35,283,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -853,000Source | -2,535,000Source | -468,000Source | 1,739,000Source | -651,000Source | 198,000Source | 1,934,000Source | -4,033,000Source | -159,000Source | 670,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 33,800,000Source | -31,498,000Source | 37,097,000Source | 10,525,000Source | 40,221,000Source | 19,987,000Source | 95,791,000Source | -22,212,000Source | 19,872,000Source | -62,665,000Source |
| Income Tax Expense (Benefit)USD | — | — | 7,183,000Source | -7,332,000Source | 12,386,000Source | 1,976,000Source | 10,729,000Source | 4,306,000Source | 17,454,000Source | -3,690,000Source | 1,093,000Source | -14,769,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 26,617,000Source | -24,166,000Source | 24,711,000Source | 8,549,000Source | 29,492,000Source | 15,681,000Source | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.19Source | -1.27Source | 1.09Source | 0.37Source | 1.31Source | 0.7Source | 3.5Source | -1.04Source | 0.86Source | -3.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.13Source | -1.27Source | 1.05Source | 0.36Source | 1.28Source | 0.69Source | 3.32Source | -1.04Source | 0.85Source | -3.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 20,074,000Source | 19,404,000Source | 21,158,000Source | 19,834,000Source | 20,914,000Source | 19,607,000Source | 20,053,000Source | 19,318,000Source | 18,001,000Source | 16,260,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 21,093,000Source | 19,404,000Source | 21,915,000Source | 20,308,000Source | 21,544,000Source | 20,046,000Source | 21,228,000Source | 19,318,000Source | 18,194,000Source | 16,260,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 20,400,000Source | 13,900,000Source | 17,400,000Source | 21,100,000Source | 18,700,000Source | 20,700,000Source | 82,500,000Source | 60,300,000Source | 52,300,000Source | 49,500,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | 93,389,000Source | 63,075,000Source | 100,158,000Source | 74,615,000Source | 93,582,000Source | 73,037,000Source | 341,310,000Source | 250,210,000Source | 181,513,000Source | 138,785,000Source |
| Costs and ExpensesUSD | — | — | 191,573,000Source | 168,851,000Source | 225,584,000Source | 197,479,000Source | 198,574,000Source | 170,928,000Source | 772,273,000Source | 613,792,000Source | 439,845,000Source | 351,668,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,693,000Source | 17,821,000Source | 12,677,000Source | 467,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 22,632,000Source | 15,748,000Source | 19,640,000Source | 23,281,000Source | 20,919,000Source | 22,891,000Source | 91,417,000Source | 67,731,000Source | 59,791,000Source | 56,972,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 103,588,000Source | -24,618,000Source | — | — |
| Interest Expense, DebtUSD | — | — | 8,279,000Source | 6,658,000Source | 7,498,000Source | 8,222,000Source | 7,552,000Source | 8,107,000Source | 32,562,000Source | 33,628,000Source | 32,469,000Source | 28,418,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -4,727,000Source | -2,331,000Source | -3,636,000Source | -5,438,000Source | -3,769,000Source | -5,484,000Source | -20,060,000Source | -17,602,000Source | -26,940,000Source | -28,052,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 26,273,000Source | -24,572,000Source | 23,000,000Source | 7,323,000Source | 29,492,000Source | 15,275,000Source | 77,180,000Source | -20,147,000Source | 17,154,000Source | -49,521,000Source |
| Other Interest and Dividend IncomeUSD | — | — | 1,257,000Source | 1,652,000Source | 1,007,000Source | 1,237,000Source | 1,005,000Source | 1,238,000Source | 4,874,000Source | 6,266,000Source | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 344,000Source | 406,000Source | 0Source | 407,000Source | 0Source | 406,000Source | 1,157,000Source | 1,625,000Source | 1,625,000Source | 1,625,000Source |
| Research and Development ExpenseUSD | — | — | 12,304,000Source | 10,128,000Source | 14,747,000Source | 16,535,000Source | 10,600,000Source | 10,564,000Source | 51,664,000Source | 44,581,000Source | 34,286,000Source | 22,318,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 1,132,000Source | 5,679,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | 2,483,000Source | 0Source | 1,711,000Source | 819,000Source | 2,063,000Source | 1,564,000Source | 6,963,000Source | 0Source | 1,679,000Source | — |
Filing attachments
tm2628706d1_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 STRICTLY CONFIDENTIAL To: ANI Pharmaceuticals, Inc., corporate identity number 3379943, domiciled in Delaware, 104 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08540 USA (the “Offeror”) Re: Irrevocable undertaking in relation to the public offer for Egetis Therapeutics AB (publ) BACKGROUND 1.1 The Offeror is considering making a voluntary public offer to acquire all outstanding shares in, and convertibles and warrants issued by, Egetis Therapeuti…
Read attachment ↗tm2628706d1_ex99-2.htm · 8-K · 2026-11-05
Exhibit 99.2 ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 in 70K males Supported by ANI’s proven track record in Rare Disease, EMCITATE® has potential to reach over $300 million in peak sal…
Read attachment ↗